Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Depression present in late life and midlife significantly increased the risk for all-cause dementia based on pooled hazard ratios (hazard ratios, 1.95 and 1.56, respectively). HealthDay News — ...

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

There was no significant sex differences in toddlers with autism spectrum disorder across 17 of 18 measures, including symptom severity, receptive and expressive language, and social attention.

Patients with acute episodic migraine consistently prioritize pain relief over other treatment attributes such as route of administration, adverse outcomes, and costs, according to study results ...

Shifting patterns in ischemic stroke mortality and death locations across US populations highlight disparities and end-of-life care needs.

HealthDay News — Military service does not appear to increase the risk of depression, according to a study published online May 29 in BMJ Military Health.

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Patients with Alzheimer disease and cognitive impairment with delayed REM sleep patterns have increased levels of brain amyloid and tau.

For adult patients with transient ischemic attack/mild stroke, disturbed sleep is associated with greater cerebral small vessel disease burden and worse cognitive outcomes.

The Food and Drug Administration has granted Fast Track designation to ATH434 for the treatment of multiple system atrophy.